Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to announce the winner of their Cancer Discovery Incubator Award, Midissia Therapeutics (Midissia). Midissia is a clinical stage immunotherapy start-up focused on immune intensification.
Currently, Midissia is based in San Francisco and incorporated in Delaware. Immunomic Therapeutics’ Cancer Discovery Incubator will provide Midissia with the opportunity to develop a proof-of-concept experiment in the Immunomic laboratories. Additionally, Midissia will receive funding, lab equipment and a unique mentorship with the Immunomic executive team for one year.